Navigation Links
Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
Date:3/12/2008

other things, for filing patents to protect the MT-39 series based both on the original work performed at MTI as well as work that will be carried out by Makoto.

Terence S. Russell, Ph.D., President and CEO of Makoto, said: "We are very pleased to have the opportunity to work with Mercury and to apply Makoto's expertise in small molecule target identification to drug discovery in metabolic disease. Type-2 diabetes is a large and growing serious medical condition for which novel therapeutics are increasingly needed."

Neal C. Birnberg, Ph.D., Mercury Therapeutics' President and CEO, said: "By finding a development partner for the MT-39 program while continuing to develop direct AMPK activators in-house, this agreement with Makoto complements Mercury's internal AMPK activator development strategy. Furthermore, by leveraging our AMPK small molecule discovery platform to identify both direct and indirect AMPK activators, this agreement increases the number of potential revenue generating opportunities for our shareholders."

About Mercury Therapeutics, Inc. (http://www.mtipharm.com)

MTI was launched in 2001, and has an exclusive license to a patent from Dartmouth College and St. Vincent's Institute for Biomedical Research in Melbourne, Australia for AMP activated protein kinase (AMPK). In June 2001, MTI launched its R&D operations following execution of a sub-license and collaboration agreement with Aventis to develop AMPK activators to treat Type-2 diabetes and obesity. In June 2004, Aventis was acquired by Sanofi, and the AMPK collaboration with MTI ended. In October, 2004: MTI secured external financing from XL TechGroup, Inc. In Q4 2005, MTI demonstrated its first preclinical proof-of-principle of active compounds in a glucose tolerance test in mice. In Q4 2006, MTI implemented a chemical design and synthesis program which led to the submission of a patent application in February 2008 cla
'/>"/>

SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
2. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
3. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
4. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
5. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
6. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
7. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
8. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
9. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
10. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
11. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- Research and Markets  has announced the addition ... Gas Chromatograph Market by Type , Technology, Spectroscopy, Gas ... Forecast to 2013 - 2020" report to their ... process analytical instrument that provides chemical composition data on ... by which companies carry out their production and improve ...
(Date:9/29/2014)... 29, 2014 Burnham Securities Inc. ("Burnham"), ... ("TCG"), a leader in healthcare venture development and ... alliance to expand the range of services each ... alliance, Burnham Securities will be supported by a ... and management in healthcare industry to build a ...
(Date:9/29/2014)... , September 29, 2014 ... for severe infections, today announced that the Biomedical Advanced ... Atox Bio with a contract valued up to $24 ... to treat Necrotizing Soft Tissue Infections (NSTI) and potentially ... end in sepsis. BARDA awarded the contract ...
(Date:9/29/2014)... (PRWEB) September 29, 2014 Westbridge ... SUPPRESS™ Herbicide EC, a highly effective new tool ... as a broad spectrum contact herbicide for post-emergent, ... food and non-food crops. The formulation is an ... Organic Materials Review Institute (OMRI) for use in ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... , , , , ... drugs to combat Alzheimer,s began journey 8 years ago , , ... of a million" , , NEW YORK, Aug. 6 ... (ADDF) , have achieved a significant milestone in their development as they advance ...
... UMEA, Sweden, August 6 Omnio Healer AB, ... anti-infection, today,announced that it has entered into a partnership ... provide process,development and cGMP production services relating to Omnio ... Based on a novel therapeutic concept for wound healing ...
... , WALTHAM, Mass., Aug. 6 Interleukin ... today that it will host a conference call and webcast on ... Company,s business developments and second quarter financial results. , , ... 719-325-4847 (international). The live webcast and replay access of the teleconference ...
Cached Biology Technology:PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 2PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan 3Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments 2Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments 3
(Date:9/29/2014)... September 29: Between 1970 and 2010 populations of ... globe dropped 52 percent, says the 2014 Living ... (WWF). This biodiversity loss occurs disproportionately in low-income ... high-income countries. , In addition to the precipitous ... to other warning signs about the overall health ...
(Date:9/29/2014)... with children at home should use ventilation when cooking ... are recommending, after a new study showed an association ... and chronic bronchitis. , "In homes where a gas ... and wheezing is higher than in homes where a ... an associate professor in the College of Public Health ...
(Date:9/29/2014)... bad rap, and understandably so. The grain-of-rice-sized insects are ... of acres in the Western U.S. and Canada over ... belief, these pests may not be to blame for ... through the region. Instead, weather and topography play a ... these bark-boring beetles. , New research led by the ...
Breaking Biology News(10 mins):Half of global wildlife lost, says new WWF report 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... When a study in her lab showed that mate ... in the activity of an enzyme that promotes HDL ... Illinois scientist Elvira de Mejia headed for Argentina where ... centuries. She returned with a five-year agreement signed ...
... taking place in London on Thursday 25 and Friday ... natural scientists with what is becoming the worlds largest ... genomics - the Economic and Social Research Council (ESRC) ... are often described as the ,genetic information, that makes ...
... 17, 2007 Just in time for Halloween, researchers are ... social stress, in an article scheduled for publication in the ... adults alike gear up for the anticipation and excitement of ... our inherent fear of the dark. Grillon ...
Cached Biology News:More on mate tea: lower cholesterol and an international agreement 2From GM farm animals to embryonic stem cell research 2From GM farm animals to embryonic stem cell research 3Social stress + darkness = increased anxiety 2
... GenePix Pro is the industry standard microarray ... combination of imaging and analysis tools, visualizations, ... GenePix Pro is included with every GenePix ... from third-party scanners and all types of ...
... ideal instrument for budget-conscious labs that want to ... Get Applied Biosystems proven PCR performance at ... without sacrificing results. Enhance productivity with ... Can Afford The Applied Biosystems 2720 ...
... Sigma-Genosys offers custom peptide synthesis with a wide ... best fit your research needs. Purity: ... Yield: 2mg-1g Sequence Length: ... Biotin, Fluorescein, N-acetylation, C-amidation, phosphorylation, D-amino acids, MAPs, ...
... handling system from Molecular Devices provides precise ... instrument. The system handles a variety of ... 384- and 1536-welland is the first to ... been optimized to dispense from four different ...
Biology Products: